Anixa Biosciences, Inc. (ANIX)
3.48
-0.12
(-3.33%)
USD |
NASDAQ |
Aug 28, 16:00
3.59
+0.11
(+3.16%)
After-Hours: 20:00
Anixa Biosciences Cash from Financing (Quarterly) : 1.249M for April 30, 2026
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| April 30, 2026 | 1.249M |
| January 31, 2026 | 1.685M |
| October 31, 2025 | 0.35M |
| July 31, 2025 | 1.929M |
| April 30, 2025 | 0.018M |
| January 31, 2025 | -0.017M |
| October 31, 2024 | 0.106M |
| July 31, 2024 | 0.149M |
| April 30, 2024 | 0.897M |
| January 31, 2024 | 2.263M |
| October 31, 2023 | 0.279M |
| July 31, 2023 | 0.003M |
| April 30, 2023 | 0.081M |
| January 31, 2023 | 0.003M |
| October 31, 2022 | -0.384M |
| July 31, 2022 | 0.829M |
| April 30, 2022 | 0.007M |
| January 31, 2022 | 0.00 |
| October 31, 2021 | 0.1436M |
| July 31, 2021 | 0.00 |
| April 30, 2021 | 25.36M |
| January 31, 2021 | 6.061M |
| October 31, 2020 | 1.403M |
| July 31, 2020 | 4.851M |
| April 30, 2020 | 1.373M |
| Date | Value |
|---|---|
| January 31, 2020 | 1.780M |
| October 31, 2019 | 0.6818M |
| July 31, 2019 | 0.5646M |
| April 30, 2019 | 2.280M |
| January 31, 2019 | 2.176M |
| October 31, 2018 | 0.7423M |
| July 31, 2018 | 1.109M |
| April 30, 2018 | 0.6774M |
| January 31, 2018 | 0.00 |
| October 31, 2017 | 1.462M |
| July 31, 2017 | 2.212M |
| April 30, 2017 | 4.203M |
| January 31, 2017 | -0.4943M |
| October 31, 2016 | -0.0261M |
| July 31, 2016 | 0.0052M |
| April 30, 2016 | 0.0182M |
| January 31, 2016 | 0.00 |
| October 31, 2015 | 0.0103M |
| July 31, 2015 | -0.2109M |
| April 30, 2015 | -0.20M |
| January 31, 2015 | 0.00 |
| October 31, 2014 | 0.0246M |
| July 31, 2014 | 3.874M |
| April 30, 2014 | -0.0493M |
| January 31, 2014 | 3.50M |
Cash From Financing Definition
Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -0.449M |
| Oncolytics Biotech, Inc. | 6.704M |
| Sangamo Therapeutics, Inc. | 26.70M |
| Sarepta Therapeutics, Inc. | 0.00 |
| Vicapsys Life Sciences, Inc. | 0.135M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.741M |
| Cash from Investing (Quarterly) | 0.422M |
| Free Cash Flow | -7.117M |
| Free Cash Flow Per Share (Quarterly) | -0.0518 |
| Free Cash Flow to Equity (Quarterly) | -1.732M |
| Free Cash Flow to Firm (Quarterly) | -1.741M |
| Free Cash Flow Yield | -6.18% |